Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

• Published in: Annals of oncology Vol. 32; no. 3; pp. 298 - 308
• Main Authors: Dreyling, M., Ghielmini, M., Rule, S., Salles, G., Ladetto, M., Tonino, S.H., Herfarth, K., Seymour, J.F., Jerkeman, M.
• Format: Journal Article
• Language: English
• Published: England Elsevier Ltd 01.03.2021
• Subjects: antibody; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Cancer and Oncology; Cancer och onkologi; chemotherapy; Clinical Medicine; follicular lymphoma; Follow-Up Studies; Health Planning Guidelines; Humans; Klinisk medicin; lenalidomide; Lymphoma, Follicular - diagnosis; Lymphoma, Follicular - epidemiology; Lymphoma, Follicular - therapy; Medical and Health Sciences; Medicin och hälsovetenskap; Neoplasm Recurrence, Local - diagnosis; Neoplasm Recurrence, Local - therapy; Neoplasm Staging; radiotherapy; Rituximab - therapeutic use; radiotherapy; antibody; lenalidomide; follicular lymphoma; chemotherapy
• ISSN: 0923-7534; 1569-8041; 1569-8041
• DOI: 10.1016/j.annonc.2020.11.008

•This updated ESMO Clinical Practice Guideline provides key recommendations on the management of follicular lymphoma.•Authorship includes a multidisciplinary group of experts from different institutions and countries in Europe and abroad, including levels of evidence and grades of recommendation where applicable.•In localised stages, combination of radiation and rituximab monotherapy may be considered.•In advanced stages, either obinutuzumab or rituximab may be combined with chemotherapy.•In early relapses, a switch of chemotherapy and antibody is recommended. In younger patients, an autologous stem-cell transplantation should be discussed.•In older patients with either early, first or later relapses, lenalidomide in combination with rituximab may be considered.